top of page

Conference Speaker Biography
- Dr Rodger Tiedemann

Programmes

Dr. Rodger Tiedemann, MBChB PhD FRACP FRCPA, is The Antony and Margaret Morris Fellow in Cancer Research, an Associate Professor at the University of Auckland and a Consultant Haematologist at Auckland City Hospital.

Dr Tiedemann worked in North America for nearly two decades, first at at Mayo Clinic in Scottsdale, and then at The Princess Margaret Cancer Center in Toronto, Canada. He remains affiliated with The Princess Margaret Cancer Centre and the University of Toronto, as a Senior Scientist and Principal Investigator of the Tiedemann Lab.

Dr. Tiedemann is a Fellow of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia. He received Medicine and Surgery degrees and a Ph.D at the University of Auckland in 1998. His doctoral studies examined the basis of superantigen-induced immune cell activation under the supervision of Dr. John Fraser. Prior to this, Dr. Tiedemann was a national representative to the 29th International Mathematics Olympiad and a prize winner in the Australian Mathematics Competition.

Following Hematology training he completed post-doctoral research in multiple myeloma (MM) at the Mayo Clinic in Scottsdale, AZ, USA and then joined the staff at Mayo Clinic as Senior Associate Consultant Hematologist and Assistant Professor at Mayo Clinic College of Medicine. From genome wide RNAi studies he identified XPO1 and MCL1 as critical vulnerabilities in MM cells. This work provided the impetus for the development of Selinexor for myeloma, which was FDA approved in 2020. After moving to Toronto, Canada, Dr Tiedemann’s research led to the discovery of immature MM progenitor cells that prevent cure with current treatments. He received an American Society of Hematology (ASH) Scholar Award in 2009 and the Canadian Cancer Society (CCS) Rawls Prize in 2018.

bottom of page